Author:
Schrijvers Rik,Debyser Zeger
Reference13 articles.
1. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012
2. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
3. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects;Airoldi;Patient Prefer Adherence,2010
4. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study;Molina;Lancet Infect Dis,2011
5. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir;Ramanathan;Clin Pharmacokinet,2011
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献